Javitt Daniel C.'s Form 4 filing
NRX Pharmaceuticals, Inc. (NRXP) · filed Dec 1, 2022
- Accession no.
- 0000880984-22-000017
- Filed
- Dec 1, 2022
- Trade date
- Nov 29-30, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $33.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Javitt Daniel C.CIK 0001864534 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2022 | common stock | SSaleDisposed | −13,730 | $1.50 | −$20,595 | 9,643,234 | Indirect | |
| Nov 30, 2022 | common stock | SSaleDisposed | −8,441 | $1.50 | −$12,661.5 | 9,634,793 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.